This trial is a double-blind randomized clinical trial of lisinopril versus losartan for the
treatment of cardiomyopathy in Duchenne Muscular Dystrophy (DMD). Both drugs are known to be
effective for the treatment of dilated cardiomyopathy. ACEi have been reported to delay the
onset and progression of left ventricle dysfunction in children with DMD. Multiple studies
show therapeutic efficacy of losartan in animals with cardiomyopathy related to muscular
dystrophy and in patients with cardiomyopathy from diverse causes. ARBs are often reserved
for patients in whom heart failure is not adequately treated or where side effects preclude
the use of an ACEi. However, in DMD, losartan might be a better choice as a first line drug
because of studies demonstrating a potential benefit for skeletal muscle in the mdx mouse.
Considering that both skeletal and cardiac muscles are major contributors of the disability
of DMD, a drug that could improve both heart and skeletal muscles simultaneously would need
consideration as the drug of choice for the cardiomyopathic DMD patient.
Phase:
N/A
Details
Lead Sponsor:
Nationwide Children's Hospital
Collaborators:
Boston Children's Hospital Boston Children’s Hospital St. Louis Children's Hospital University of California, Davis University of Minnesota University of Minnesota - Clinical and Translational Science Institute Unverisity of Kansas Medical Center